Comparative effectiveness of lipid-Modifying agents
This evidence report was commissioned by the Agency for Healthcare Research and Quality (AHRQ) to address the following key questions: Key Question 1. For patients who require intensive lipid-modifying therapy, what are the comparative long-term benefits and rates of serious adverse events of coadmi...
Main Author: | |
---|---|
Corporate Authors: | , |
Format: | eBook |
Language: | English |
Published: |
Rockville, MD
Agency for Healthcare Research and Quality
2009, 2009
|
Series: | Comparative effectiveness review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | This evidence report was commissioned by the Agency for Healthcare Research and Quality (AHRQ) to address the following key questions: Key Question 1. For patients who require intensive lipid-modifying therapy, what are the comparative long-term benefits and rates of serious adverse events of coadministration of different lipid-modifying agents (i.e., a statin plus another lipid-modifying agent) compared with higher dose statin monotherapy? Key Question 2. Do these regimens differ in reaching LDL targets (or other surrogate markers), short-term side effects, tolerability, and/or adherence? Key Question 3. Compared with higher dose statins and to one another, do combination regimens differ in benefits and harms within subgroups of patients? |
---|---|
Item Description: | Title from PDF t.p. - "September 2009.". - Mode of access: Internet |
Physical Description: | 1 PDF file (various pagings) |